Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24922695
PII: 34/6/3205
Knihovny.cz E-resources
- Keywords
- CEA, CYFRA 21-1, EGFR-TKI, NSCLC, Tumor marker, erlotinib, prediction,
- MeSH
- Adenocarcinoma blood drug therapy mortality MeSH
- Antigens, Neoplasm blood MeSH
- Quinazolines therapeutic use MeSH
- Adult MeSH
- ErbB Receptors antagonists & inhibitors genetics MeSH
- Erlotinib Hydrochloride MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Carcinoembryonic Antigen blood MeSH
- Keratin-19 blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Mutation genetics MeSH
- Biomarkers, Tumor blood MeSH
- Lung Neoplasms blood drug therapy mortality MeSH
- Follow-Up Studies MeSH
- Carcinoma, Non-Small-Cell Lung blood drug therapy mortality MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Carcinoma, Squamous Cell blood drug therapy mortality MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- antigen CYFRA21.1 MeSH Browser
- Antigens, Neoplasm MeSH
- Quinazolines MeSH
- EGFR protein, human MeSH Browser
- ErbB Receptors MeSH
- Erlotinib Hydrochloride MeSH
- Protein Kinase Inhibitors MeSH
- Carcinoembryonic Antigen MeSH
- Keratin-19 MeSH
- Biomarkers, Tumor MeSH
BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
